The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials,

This series was created by the IDDI Patient Engagement and Empowerment Workstream, of the Pulmonary Vascular Research Institute (PVRI), whose members are Hall Skaara, Louise Bouman, Jamie Myrah, Colleen Brunetti, Luke Howard, Gil Golden, Vera Toth-Fejel, Wendy Gin-Sing. The series explains what clinical trials are, how they work, and what it means to take part. All […]

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials, Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026

The findings of a multi-center randomized controlled trial investigating the long-term efficiency of rehabilitation in patients with pulmonary arterial hypertension was published in the Annals of the American Thoracic Society on July 20, 2026. The study followed 47 patients with stable pulmonary arterial hypertension across 9 French centers, looking at the long-term impact of a

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 Read Post »

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026

In a recent LinkedIn post Prof. Werner Seeger writes that the GoDeep meta-registry analysis about the predictive power of pulmonary artery stiffness – right ventricular interplay in mild pulmonary hypertension (PH) is now online. He reports that in the analysis, notably, parameters integrating pulsatile vascular load and interdependent right ventricular function possess predictive power independent

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 Read Post »

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026

The US Food and Drug Administration (FDA) has accepted for review a New Drug Application from United Therapeutics Corporation for ralinepag, an investigational prostacyclin IP receptor agonist intended to treat pulmonary arterial hypertension (PAH). The filing rests on results from the Phase III ADVANCE OUTCOMES study See our previous article on this topic here. Read more at

US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026 Read Post »

Safety of exercise after pulmonary endarterectomy: a systematic review, European Respiratory Journal Open Research 2026

A systematic review recently published in the European Respiratory Journal Open Research looked at whether early exercise after pulmonary endarterectomy (PEA) surgery in chronic thromboembolic pulmonary hypertension (CTEPH) is safe and feasible, given that post-operative cardiac remodelling needs to be balanced against the benefits of getting moving early. Searching the AMED, CINAHL, Embase, and MEDLINE

Safety of exercise after pulmonary endarterectomy: a systematic review, European Respiratory Journal Open Research 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026

Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its primary endpoint — improvement in

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026 Read Post »

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available

A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill patients in the Intensive Care

Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available Read Post »

“United for better breathing – Co-creating care: patients as equal partners”, European Respiratory Society (ERS) webinar on August 31, 2026, 17:00–18:00 CEST

This European Respiratory Society webinar, chaired by Prof. Hilary Pinnock and Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and President of the Dutch Pulmonary Hypertension Foundation, is the penultimate session of the pre-Congress webinar series – developed in collaboration with the European Lung Foundation – that introduces the European Respiratory Society Congress 2026

“United for better breathing – Co-creating care: patients as equal partners”, European Respiratory Society (ERS) webinar on August 31, 2026, 17:00–18:00 CEST Read Post »

Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society

Krishma Kaur and his cousin Sean Bhaker, UK citizens, have decided to take on the challenge of climbing Mount Kilimanjaro to raise money for Alzheimer’s Society and the UK Pulmonary Hypertension Association PHA UK. All money raised will be donated directly to these two charities. Krishma and Sean have launched a Go Fund campaign to

Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society Read Post »

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition

A narrative review on inhaled pulmonary vasodilators (iPVs) in perioperative pulmonary hypertension (PH) management was published recently in Key points: Background: Pulmonary hypertension significantly raises perioperative morbidity/mortality risk, especially in cardiac and high-risk non-cardiac surgery. Traditional IV vasodilators (nitroglycerin, sodium nitroprusside) lack pulmonary selectivity and cause systemic hypotension. Established agents: The review compares five main

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition Read Post »

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026

For 30 years, pulmonary arterial hypertension (World Health Organisation, WHO, Group 1 pulmonary hypertension) treatment relied on three vasodilator-based pathways: endothelin receptor antagonists (bosentan, ambrisentan, macitentan), the nitric oxide/cGMP pathway (sildenafil, tadalafil, riociguat), and prostacyclin pathway agents (treprostinil, epoprostenol, selexipag, etc.). These improve symptoms and slow progression but don’t modify the underlying vascular disease, and

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification, Clinical and Translational Science, July 31, 2026 Read Post »

From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide

he pathway to medical breakthroughs is often laden with surprises, errors, and serendipity, reads and article in a magazine called Mirage. The article dates back to 2023 but we found it still relevant and interesting as it mentions two iaccidental discoveries, warfaring and sildenail citrate that are have transformed the care of pulmonary arterial hypertension

From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide Read Post »

How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026

A cross-sectional study surveyed 111 adults with pulmonary hypertension (see table below for different forms), predominantly UK-based, White, and female, to examine sleep problems and their psychological/quality-of-life impact. The design and procedure of the study were developed in association with the UK Pulmonary Hypertension Association, PHA UK, and medical experts in pulmonary hypertension. Key findings:

How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026 Read Post »

World Health Organization opens public consultation on its first global strategy for organ donation and transplant, deadline August 31st 2026

The World Health Organization (WHO) has opened public consultation (until 31 August 2026) on its first draft global strategy for donation and transplantation of human cells, tissues and organs — following up on World Health Organization resolution 77.4 (2024). Key points: Who should participate Policy makers, regulators, service developers-providers, professional bodies, clinical and technical experts, scientists

World Health Organization opens public consultation on its first global strategy for organ donation and transplant, deadline August 31st 2026 Read Post »

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026

Insmed announced on July 16 positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). The OLE study is a non-placebo-controlled trial and was designed to evaluate the long-term safety, tolerability, and effectiveness of

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026 Read Post »

What’s new in Pulmonary Hypertension on the Knowledge Sharing Platform in July 2026

This month’s round-up brings together a mix of clinical trial data, emerging science, and a few broader conversations about care. Beyond the data, it also touches on the human side of PH care: a look at quality of life and mental health in patients on prostacyclin therapy, and a conversation on “caring for the whole

What’s new in Pulmonary Hypertension on the Knowledge Sharing Platform in July 2026 Read Post »

The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning

The Pulmonary Vascular Research Iinstitute (PVRI’s) Access to Care Workstream has launched a new, free online service from clinicians around the world to bring anonymised complex pulmonary hypertension cases for discussion with a tailored panel of specialists. Global PH Consult is open to clinicians everywhere, with a primary focus on supporting those in low and

The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning Read Post »

TRANSLATE »
Scroll to Top